Key Developments: Cadence Pharmaceuticals Inc (CADX.O)
7.18USD
17 May 2013
$-0.10 (-1.37%)
$7.28
$7.34
$7.38
$7.17
300,904
305,569
$7.53
$2.56
Latest Key Developments (Source: Significant Developments)
Cadence Pharmaceuticals Inc Reaffirms FY 2013 Product Revenue Guidance-Conference Call
Cadence Pharmaceuticals Inc announced that its is reaffirming the net product revenue from sales of OFIRMEV for the full year 2013 will range from $94 million to $100 million. Full Article
Cadence Pharmaceuticals Inc Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV (acetaminophen) Injection
Cadence Pharmaceuticals Inc announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories, a member of the Bristol Myers Squibb group of companies, through December 31, 2018. Additionally, the Company has terminated its development and supply agreement for OFIRMEV in glass vials with Baxter Healthcare Corporation. Full Article
Cadence Pharmaceuticals Inc Issues Q4 2012 Product Revenue Guidance
Cadence Pharmaceuticals Inc announced that for the fourth quarter of 2012, a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV (acetaminophen) injection, of approximately $17.1 million. Full Article
Cadence Pharmaceuticals Inc Announces Termination Of Option Agreement to Acquire Incline Therapeutics, Inc.
Cadence Pharmaceuticals Inc announced that it has entered into an agreement to terminate its exclusive option to acquire privately-held Incline Therapeutics, Inc., or Incline. Under the waiver, consent and option termination agreement signed by Cadence and Incline, upon the closing of the proposed acquisition of Incline by The Medicines Company, Cadence would receive a payment of approximately $13 million to buy-out Cadence's interest in, and terminate Cadence's rights with respect to, the option agreement. Additionally, Cadence would receive approximately $1.5 million related to the purchase by The Medicines Company of the shares of Incline common stock held by Cadence, subject to adjustment, and, potentially, a pro rata share of future milestone payments. The acquisition of Incline by The Medicines Company is subject to the satisfaction or waiver of customary closing conditions, and is currently expected to close in January, 2013. Full Article
Cadence Pharmaceuticals Inc Announces Voluntary Recall Of One Lot Of OFIRMEV (Acetaminophen) Injection
Cadence Pharmaceuticals Inc announced the voluntary recall of a single lot of OFIRMEV (acetaminophen) injection. Cadence has notified the U.S. Food and Drug Administration of the recall. The recall of OFIRMEV lot number V005710 was initiated due to the presence of an unidentified, visible particle in one vial of this lot during routine stability testing. Lot V005710 was distributed by Cadence to hospitals, wholesalers and distributors beginning in January 2011, and Cadence believes that fewer than 1,000 vials currently remain in the marketplace. Cadence has not received any reports of adverse patient events associated with particulate matter in the product, and has undertaken the recall as a precautionary measure. Full Article
Cadence Pharmaceuticals, Inc. Announces Completion Of Public Offering Of Common Stock, Including Full Exercise Of Over-Allotment Option By Underwriters
Cadence Pharmaceuticals, Inc. announced the closing of its previously announced public offering of 21,800,000 shares of its common stock, including 2,800,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a public offering price of $3.75 per share. The net proceeds from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $77.4 million . Deutsche Bank Securities Inc. acted as sole book-running manager, Leerink Swann LLC acted as co-lead manager and Cowen and Company, LLC acted as co-manager for the offering. Full Article
Cadence Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock
Cadence Pharmaceuticals, Inc. announced that it has priced an underwritten public offering of 19,000,000 shares of its common stock at a price to the public of $3.75 per share. The net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.4 million. Cadence has granted the underwriters for the offering a 30-day option to purchase up to an additional 2,800,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about November 18, 2011, subject to customary closing conditions. Deutsche Bank Securities Inc. is acting as sole book-running manager, Leerink Swann LLC is acting as co-lead manager and Cowen and Company, LLC is acting as co-manager for the offering. Full Article
Cadence Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
Cadence Pharmaceuticals, Inc. announced its intention to offer and sell $75 million worth of shares of its common stock in an underwritten public offering. Cadence also expects to grant to the underwriters for the offering a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Deutsche Bank Securities Inc. is acting as sole book-running manager and Leerink Swann LLC is acting as lead manager for the offering. Full Article
UPDATE 1-Medicines Co to spend $300 mln to boost hospital products line
* To pay $105 mln to license Bristol-Myers' blood-loss control device
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
